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Fig. S1. EPAC design and functionalization. Fig. S2 . EPAC-captured EV characterization. Fig. S3 . Western blot analysis of isolated EVs from SK-MEL-28 and MCF7 cells. Fig. S4 . Performance evaluation of the anti-CD63, anti-CD9, or anti-CD81 functionalized EPAC for detection of MCSP-positive EVs from SK-MEL-28 cells. Fig. S5 . Monitoring the changes of individual biomarker levels in EVs from drug-treated melanoma cell lines, using the anti-CD63 functionalized EPAC. Fig. S6 . Effect of cell debris on the anti-CD63 functionalized EPAC performance. Fig. S7 . Anti-MCSP functionalized EPAC specificity. Fig. S8 . The ErbB3 expression in EVs derived from melanoma patient (P1 to P10) and normal plasma (H1 to H5) samples, measured with a commercial ELISA kit. Fig. S9 . The anti-MCSP functionalized EPAC for tracking EV phenotypic changes of patients 18 to 23 during targeted therapies. Table S1 . The anti-MCSP functionalized EPAC for measurements of plasma EVs from 12 healthy donors (H1 to H12) and 8 melanoma patients (P16 to P23). Table S2 . Demographic data for melanoma patients and healthy donors. µm. An electrode pair consists of a small (100 µm width) and large (400 µm width) electrodes that are spaced by a distance of 50 µm. (D) EPAC functionalization. The EPAC device is covered with a PDMS slab consisting of five parallel channels aligned with the array of asymmetric electrodes; each 3.5 cm long, 400 µm wide, and 500 µm high (pictures not shown). EPAC channels are sequentially incubated with biotinylated bovine serum albumin for 2 h, streptavidin for 1 h, biotinylated capture antibodies for 2 h, and bovine serum albumin for 0.5 h at room temperature. After each incubation step, the channels are washed with PBS buffer to remove excess reagents. After functionalization with capture antibodies, EPAC is ready for EV analyses. Essentially, EPAC first performs EV capture, followed by in situ SERS mapping for EV characterization. EPAC also generates a nanomixing force by applying an electric potential difference to increase the diffusion of EV samples and SERS nanotags. The blood samples were collected during the treatment. The radiological imaging test showed that this patient obtained a partial response at the second visit and progressed at the third visit. (C) Patient 20 received the combination therapy of BRAF and MEK inhibitors for 52 cycles (no stop date of trial recorded). The radiological imaging test indicated that this patient responded partially to the treatment at the second visit and then progressed at the third visit. The significant differences (P < 0.05) between each melanoma patients and the mean values of healthy controls were evaluated by one-way ANOVA and labeled with *.
